JP2011246469A5 - - Google Patents

Download PDF

Info

Publication number
JP2011246469A5
JP2011246469A5 JP2011138647A JP2011138647A JP2011246469A5 JP 2011246469 A5 JP2011246469 A5 JP 2011246469A5 JP 2011138647 A JP2011138647 A JP 2011138647A JP 2011138647 A JP2011138647 A JP 2011138647A JP 2011246469 A5 JP2011246469 A5 JP 2011246469A5
Authority
JP
Japan
Prior art keywords
alkyl
pivaloyl
mesylate
benzoyl
hydrogen succinate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011138647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011246469A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011246469A publication Critical patent/JP2011246469A/ja
Publication of JP2011246469A5 publication Critical patent/JP2011246469A5/ja
Pending legal-status Critical Current

Links

JP2011138647A 1998-11-05 2011-06-22 B型肝炎ウイルス活性を持ったヌクレオシド Pending JP2011246469A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10711698P 1998-11-05 1998-11-05
US11565399P 1999-01-13 1999-01-13
US60/107,116 1999-01-13
US60/115,653 1999-01-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000579613A Division JP2002528554A (ja) 1998-11-05 1999-11-05 B型肝炎ウイルス活性を持ったヌクレオシド

Publications (2)

Publication Number Publication Date
JP2011246469A JP2011246469A (ja) 2011-12-08
JP2011246469A5 true JP2011246469A5 (enExample) 2012-09-06

Family

ID=26804401

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000579613A Withdrawn JP2002528554A (ja) 1998-11-05 1999-11-05 B型肝炎ウイルス活性を持ったヌクレオシド
JP2011138647A Pending JP2011246469A (ja) 1998-11-05 2011-06-22 B型肝炎ウイルス活性を持ったヌクレオシド

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000579613A Withdrawn JP2002528554A (ja) 1998-11-05 1999-11-05 B型肝炎ウイルス活性を持ったヌクレオシド

Country Status (13)

Country Link
US (1) US6458773B1 (enExample)
EP (1) EP1124839B1 (enExample)
JP (2) JP2002528554A (enExample)
KR (1) KR100618028B1 (enExample)
CN (1) CN1216893C (enExample)
AT (1) ATE315574T1 (enExample)
AU (1) AU774720B2 (enExample)
BR (1) BR9915555A (enExample)
CA (1) CA2348470C (enExample)
DE (1) DE69929460D1 (enExample)
IL (2) IL142983A0 (enExample)
MX (1) MXPA01004504A (enExample)
WO (1) WO2000026225A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008609B1 (ru) * 1998-02-25 2007-06-29 Эмори Юниверсити 2'-фторнуклеозиды
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) * 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
US7589077B2 (en) 2001-05-18 2009-09-15 Rakesh Kumar Antiviral nucleosides
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
US20040067877A1 (en) 2002-08-01 2004-04-08 Schinazi Raymond F. 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
DE60329211D1 (de) * 2002-10-31 2009-10-22 Metabasis Therapeutics Inc Cytarabin-monophosphate prodrugs
ES2624353T3 (es) 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
MXPA05006230A (es) 2002-12-12 2005-09-20 Idenix Cayman Ltd Proceso para la produccion de nucleosidos ramificados-2'.
ES2422290T3 (es) 2005-12-23 2013-09-10 Idenix Pharmaceuticals Inc Procedimiento para preparar un producto intermedio sintético para la preparación de nucleósidos ramificados
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4841039A (en) 1986-05-01 1989-06-20 Emory University 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US4916122A (en) 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4681933A (en) 1986-05-01 1987-07-21 University Of Georgia Research Foundation, Inc. 2',3'-dideoxy-5-substituted uridines and related compounds as antiviral agents
US5084445A (en) 1986-05-01 1992-01-28 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine
US5077279A (en) 1986-05-01 1991-12-31 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
US5190926A (en) 1987-01-28 1993-03-02 University Of Georgia Research Foundation, Inc. 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents
NZ228645A (en) 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5041449A (en) 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
DD293498A5 (de) 1989-07-20 1991-09-05 Zi Fuer Molekularbiologie Der Adw,De Verfahren zur herstellung eines mittels fuer die behandlung oder prophylaxe von hepatits-infektionen bei mensch und tier
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DE4224737A1 (de) 1992-07-27 1994-02-03 Herbert Prof Dr Schott Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
EP0717628A4 (en) * 1993-09-10 1999-05-26 Univ Emory NUCLEOSIDES WITH ACTIVITY AGAINST THE HEPATITIS B VIRUS
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
US5559101A (en) 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
PT831852E (pt) 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
JPH11512397A (ja) 1995-09-07 1999-10-26 ユニバーシティー オブ ジョージア リサーチ ファウンデーション,インコーポレイテッド 治療用アジド化合物
DE69721339T2 (de) 1996-10-16 2004-01-22 Ribapharm, Inc., Costa Mesa Monozyklische l-nukleoside, analoga und ihre anwendungen

Similar Documents

Publication Publication Date Title
JP2011246469A5 (enExample)
JP2013518107A5 (enExample)
JP2013508279A5 (enExample)
JP2017531038A5 (enExample)
ME02321B (me) Antivirusna jedinjenja
JP2013534248A5 (enExample)
JP2013542247A5 (enExample)
JP2015500843A5 (enExample)
JP2010529118A5 (enExample)
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
JP2010529147A5 (enExample)
JP2012184234A5 (enExample)
JP2013509429A5 (enExample)
JP2011251968A5 (enExample)
JP2013537203A5 (enExample)
JP2017523225A5 (enExample)
JP2013537423A5 (enExample)
JP2013519645A5 (enExample)
JP2012144574A5 (enExample)
JP2012255026A5 (enExample)
JP2015505296A5 (enExample)
JP2013512277A5 (enExample)
JP2014521744A5 (enExample)
JP2016503797A5 (enExample)
JP2011518833A5 (enExample)